In December 2018, C4 Therapeutics and Biogen entered into a strategic collaboration to use C4T’s TORPEDO® platform to discover and develop potential new treatments for neurological conditions, such as Alzheimer’s disease and Parkinson’s disease. Under the agreement, C4T provides expertise and research services in targeted protein degradation and Biogen provides neuroscience expertise and drug development capabilities. Under this collaboration, Biogen and C4T research potential targets together and Biogen will advance candidates developed during this collaboration through clinical development and potential commercialization.
Partner with Us
Interested in partnering with us to leverage our MonoDAC℠ or BiDAC℠ research and development capabilities to bring degrader-based medicines to patients?Email Us To Collaborate